New immune cell therapy tested for Tough-to-Treat ovarian cancer
NCT ID NCT06646627
Summary
This early-stage trial is testing a new type of personalized immune cell therapy called B7-H3 CAR-T cells in adults with ovarian cancer that has returned and stopped responding to standard platinum chemotherapy. The study aims to find the safest dose and see if these modified immune cells can be reliably manufactured. It will enroll 48 participants at Stanford University to assess safety and early signs of effectiveness.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Stanford University
RECRUITINGPalo Alto, California, 94304, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.